Dog winks next to a piggy bank with money.

Learn More About How Therapeutic Vision is Advancing Innovative Therapeuties For Sensory Preservation in Humans and Companion Animals

Company Overview

Therapeutic Vision, Inc., based in Omaha, Nebraska, is a pioneering pharmaceutical research company dedicated to preventing vision loss caused by age-related and diabetic conditions. Our mission is to advance therapies that protect against cataracts, neurodegeneration, and oxidative stress while preserving eyesight and quality of life for both humans and companion animals.

Expertise & Research Leadership

  • Cataract Research & Consultation – Recognized experts in the toxicological mechanisms driving lens changes, including drug-induced cataracts. We provide consultative services to pharmaceutical companies and research institutions, improving the safety of emerging therapeutics.
  • Neuroprotection & Oxidative Stress – Our research links oxidative imbalance to cataracts, diabetic complications, and neurodegenerative diseases and injuries that affect neural eye tissues, the inner ear and brain, creating opportunities for breakthrough therapies for sensory loss and neuroprotection from injuries.

Grant-Supported Innovation

Our research programs have been funded by prestigious federal and state grants, validating both our scientific expertise and commercial potential)

Kinostat® – A Revolutionary Treatment for Canine Diabetic Cataracts

Diabetic cataracts are a common complication in dogs with diabetes mellitus, often leading to vision impairment and blindness. Kinostat is a groundbreaking treatment developed to slow or prevent the onset of cataracts in diabetic canines. Our research and development efforts for Kinostat have been supported by several significant grants:

  • NIH 1R43 EY018013-01A – Initial funding for the development of Kinostat as a treatment for canine diabetic cataracts.
  • NIH 2R44 EY018013-02A – Follow-up funding to expand research and refine the therapeutic application and initiate a clinical trial..
  • NIH 2R44 EY018013-2B – Further support for advancing Kinostat toward clinical applications.
  • NIH CAP Development Grant – Support for commercialization and broader implementation of Kinostat.
  • Nebraska Small Business Innovation Research Initiative (SBIR) Matching Grant – Additional state-level funding to further develop and optimize Kinostat.
  • FDA Minimum Use in a Major Animal Species (MUMS) designation Covers FDA user fees and allows for 7 years of market noncompetition.

These funding sources have played a critical role in moving Kinostat from an initial concept to a viable therapeutic option for canine patients. The promising results from our clinical studies indicate that Kinostat has the potential to greatly improve the quality of life for diabetic dogs by preserving their vision.

Multifunctional Redox Modulators (MFRMsTM) – A New Frontier in Anti-Cataract Therapy and Neuroprotection

Cataracts are often linked to oxidative stress, which damages the proteins and fibers in the eye’s lens. Our research into MFRMs originally focuses on developing antioxidants that counteract oxidative damage, thereby preventing or slowing cataract formation. However, it then expanded to targeting ferroptosis associated with retinal degenerations, hearing loss, cognition changes and neural tissue damage,

  • NIH 1R21 EY016460-01 – This grant has provided crucial funding for our investigation into multifunctional antioxidants as a means of preventing cataract formation. By developing compounds that mitigate oxidative stress and enhance lens health, we are working toward a novel approach in cataract prevention and treatment.
  • Drug Discovery Foundation 13-2471R2 – MFRM HK-2 prevented amyloid beta formation in the brain, retina, and lens of transgenic Alzheimer’s mice.
  • NIH R21EY023679-01 – This study employed in silico molecular attributes to define the ocular distribution of MFRMs to the cornea, iris, lens, ciliary processes, vitreous and neural retina of the eye.
  • NIH 1R43DC016766-01 – Multifunctional Antioxidant to Prevent Noise-Induced Hearing Loss
  • NIH Nebraska Small Business Innovation Research Initiative (SBIR) Matching Grant 
  • 1 R43 DC020687 – Effect of MFRM HK-2 on Acoustic Blast Overpressure and Cognitive Function. 
  • Nebraska Small Business Innovation Research Initiative (SBIR) Matching Grant 2022 -2024

Impact: Novel oral compounds with dual antioxidant and metal-binding mechanisms; broad applications in cataracts, age-related macular degeneration, diabetic retinopathy, neurodegeneration resulting in hearing loss, and cognition.

Antioxidant Nutraceutical antioxidants Because MFRMS are required to undergo stringent FDA development roadmaps, we also developed and patented topical antioxidant nutraceutical formulation of natural antioxidants which when combined can mimic our original anticataract MFRM. It has been licensed for the Veterinary Market to Aventix Animal Health as an FDA-sanctioned OTC veterinary device that is currently generating royalty revenue. As a strong topical antioxidant formulation, its clinical efficacy is beneficial for treating dry eye, slowing cataract development, and removing tear staining cause by the oxidation of iron in dog tears. Entry into the Human Market entry is planned as Therapeutic Eye Health to target the $3.4B global dry eye disease market.

Therapeutic Vision is committed to:

  • Expanding research initiatives in diabetic retinopathy, neurodegenerative eye diseases, and cataract prevention.
  • Bringing Kinostat to market for veterinary and human applications.
  • Developing MFRMs as breakthrough neuroprotective agents across ophthalmology, audiology, and brain damage.
  • Forming strategic collaborations and licensing partnerships to accelerate commercialization.

Why It Matters

Our work not only improves understanding of sensory health but also contributes to the broader fields of toxicology and neuroprotection. With a dual focus on human and veterinary medicine, Therapeutic Vision is uniquely positioned to deliver therapies that address both immediate market needs and long-term healthy aging.

👉 We are shaping the future of sensory preservation—ensuring that millions of people and animals worldwide can maintain their sight, hearing, cognition, and quality of life.

Key Milestones

  • 2026: Kinostat® veterinary launch
  • 2027: Therapeutic Vision Eye Health human nutraceutical launch
  • 2028: Human Kinostat launch
  • Ongoing: MFRMs™ preclinical advancement